Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 169.54M P/E - EPS this Y 91.10% Ern Qtrly Grth -
Income -98.5M Forward P/E 12.79 EPS next Y 238.90% 50D Avg Chg 23.00%
Sales 277.79M PEG -0.54 EPS past 5Y - 200D Avg Chg -57.00%
Dividend N/A Price/Book N/A EPS next 5Y 16.90% 52W High Chg -80.00%
Recommedations 2.10 Quick Ratio 1.42 Shares Outstanding 196.22M 52W Low Chg 60.00%
Insider Own 0.50% ROA 1.05% Shares Float 194.82M Beta 1.00
Inst Own 70.55% ROE - Shares Shorted/Prior 38.09M/41.73M Price 1.79
Gross Margin 61.12% Profit Margin -35.46% Avg. Volume 2,624,620 Target Price 7.59
Oper. Margin 3.49% Earnings Date Nov 5 Volume 7,117,172 Change 5.92%
About Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Esperion Therapeutics, Inc. News
12/18/24 Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
12/13/24 Esperion Announces $210 Million Convertible Debt Financing
12/12/24 Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
12/03/24 ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
12/02/24 Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
11/26/24 Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
11/21/24 Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
11/18/24 Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
11/08/24 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/08/24 Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
11/07/24 Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
11/07/24 Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
11/07/24 Esperion Therapeutics: Q3 Earnings Snapshot
11/07/24 Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
11/04/24 Esperion to Participate in Upcoming Jefferies London Healthcare Conference
10/31/24 Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
10/31/24 Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
10/24/24 Esperion to Report Third Quarter 2024 Financial Results on November 7
10/17/24 Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings
10/03/24 Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Warren Eric Chief Commercial Off.. Chief Commercial Officer Sep 20 Sell 1.245 742 924 68,318 09/21/23
Koenig Sheldon L. President and CEO President and CEO May 09 Buy 1.2596 20,000 25,192 312,816 05/10/23
Warren Eric Chief Commercial Off.. Chief Commercial Officer Mar 07 Sell 5.055 5,090 25,730 48,572 03/08/23
Koenig Sheldon L. President and CEO President and CEO Mar 07 Sell 5.056 5,441 27,510 194,815 03/08/23
Foody Joanne M. Chief Medical Office.. Chief Medical Officer Mar 07 Sell 5.065 3,884 19,672 103,060 03/08/23
Warren Eric Chief Commercial Off.. Chief Commercial Officer Aug 31 Buy 7.46 1,000 7,460 54,024 08/31/22
Koenig Sheldon L. President and CEO President and CEO Aug 05 Buy 5.8041 8,606 49,950 198,771 08/08/22
Koenig Sheldon L. President and CEO President and CEO Mar 17 Sell 4.58 571 2,615 194,717 03/18/22